AUTHORS
Hanny Al-Samkari, MD, Ju-Hyeun Kim, PharmD, PhD2, Yichuan Grace Hsieh, PhD, RN3, Janet Boyle-Kelly, MSN, RN4, Marykate E Murphy, BSN, RN5, Greg Belsky, BS6, Tran Le, PhD7, Christopher Herrick, MBA8, Adelina Vartanian, PharmD9, Scott Stryker, MD, DrPH10, Shawn Murphy, MD, PhD11
AFFILIATIONS
1 Harvard Medical School, Boston, Massachusetts, United States, Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, United States
2 Amgen Inc., Thousand Oaks, California, United States
3 Harvard Medical School, Boston, Massachusetts, United States, Mass General Brigham, Somerville, Massachusetts, United States
4 Mass General Brigham, Somerville, Massachusetts, United States
5 Mass General Brigham, Somerville, Massachusetts, United States
6 Mass General Brigham, Somerville, Massachusetts, United States
7 Mass General Brigham, Somerville, Massachusetts, United States
8 Mass General Brigham, Somerville, Massachusetts, United States
9 Amgen Inc., Thousand Oaks, California, United States
10 Amgen Inc., Thousand Oaks, California, United States
11 Harvard Medical School, Boston, Massachusetts, United States, Mass General Brigham, Somerville, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
ABSTRACT
Introduction
Persistent chemotherapy-induced thrombocytopenia (CIT) leads to increased bleeding risks and chemotherapy dose reductions and treatment delays that may compromise oncologic outcomes. Romiplostim has demonstrated safety and efficacy for persistent CIT in multiple prospective trials, most recently the phase 3 RECITE trial in patients with gastrointestinal cancers receiving oxaliplatin-based regimens. However, large studies critically evaluating long-term romiplostim effectiveness and safety for CIT across clinically complex populations with diverse tumor types and antineoplastic regimens remain limited.
Methods
Adults with solid tumors receiving ≥3 doses of romiplostim for persistent CIT between July 1, 2009, and December 31, 2023, were identified across the Mass General Brigham (MGB) health system and Dana-Farber Cancer Institute. Data were collected from the Research Patient Data Registry and manual chart review by MGB personnel with adjudication of all hematologic events by a classical hematologist. Platelet response was defined as a platelet count ≥100×109/L and an increase of ≥30×109/L from baseline (without platelet transfusion in the preceding 7 days). First and subsequent occurrences of all thrombocytopenia-related chemotherapy dose modifications (TDM; delay, reduction, omission, or discontinuation), bleeding events, and thrombotic events were collected, and secondary malignancies and myelodysplastic syndromes (MDS) were assessed for up to 5 years following romiplostim initiation. All events were included regardless of causality attribution to romiplostim. The MGB IRB approved the study (No. 2024P003283) and waived informed consent.
Results
A total of 349 patients were included; median age was 64 (range 23–88); 56% female; 83% White. Median follow-up was 380 days (IQR 162–600). Overall, 69% had stage IV cancer, 35% chronic liver disease, 22% recent bleeding, 12% active infection, 10% prior venous thrombotic events, reflecting a clinically high-risk oncology population. Tumor types were primarily gastrointestinal (58%), followed by gynecologic (15%), breast (9%), and respiratory (7%). Most patients (75%) received platinum- or gemcitabine-based regimens. Patients received a median of 10 romiplostim doses (IQR 5–22, max 99), with initial and median doses of 2 µg/kg (IQR 2–3) and 3 µg/kg (IQR 2–4). Median baseline platelet count was 75×109/L (IQR 55–93). Known predictors of romiplostim non-response (bone marrow tumor invasion, prior pelvic irradiation, or prior temozolomide use) were found in 30% of patients. Reasons for romiplostim discontinuation included antineoplastic regimen completion (n=187), clinician decision (n=131), transition to palliative care (n=86), and treatment-related safety concerns (n=7).
Within the first 28 days, platelet response rate was 82% (n=285), with a median time to response of 14 days (IQR 7–21). TDM occurred in 20% of patients through day 112 after romiplostim initiation. Rates of major or clinically relevant non-major bleeding events and hospitalized bleeding events were 21.7 (95% CI 13.9–32.3) and 23.5 (95% CI 15.4–34.4) per 100 person-years (PY), respectively, with crude event proportions of 6.3% and 6.6%; 50% were gastrointestinal in origin. Rates of venous thrombotic, arterial thrombotic, and hospitalized thrombotic events were 22.6 (95% CI 14.6–33.4), 6.3 (95% CI 2.5–13.0), and 10.8 (95% CI 5.6–19.0) per 100 PY, respectively, with crude event proportions of 6.9%, 1.7%, and 2.9%. Rates of MDS and secondary malignancies were 1.3 (95% CI 0.4–2.9) and 0.3 (95% CI 0.0–1.4) per 100 PY, respectively.
Conclusion
To our knowledge, this is the largest study describing romiplostim use in CIT to date, with the longest patient follow-up and exposure duration to date, and utilized rigorous methodology including manual chart review and hematologist adjudication. Romiplostim was highly effective in managing CIT, with improved platelet counts and low rates of TDM and bleeding in a clinically challenging population. Thrombotic and MDS event rates were consistent with those reported in similar clinically complex advanced cancer populations. These findings support the effectiveness of romiplostim for CIT across diverse solid tumor types and antineoplastic regimens, with no new safety concerns identified, in a large real-world population.
This project was funded in part with Federal funds from the Biomedical Advanced Research and Development Authority (Contract No. 75A50119C00061).
DISCLOSURES
Hanny Al-Samkari, MD: Atavistik - Research Funding; Sanofi - Research Funding; Amgen - Research Funding; SOBI - Research Funding; Novartis - Research Funding; Alnylam - Research Funding; Vaderis - Research Funding; Tectonic - Research Funding; Argenx - Research Funding; Agios Pharmaceuticals - Research Funding; Alpine Immune Sciences - Research Funding; Pharmacosmos - Research Funding; Novartis - Consultancy (Includes expert testimony); Agios Pharmaceuticals - Consultancy (Includes expert testimony); Alnylam - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Argenx - Consultancy (Includes expert testimony); SOBI - Consultancy (Includes expert testimony); Tectonic - Consultancy (Includes expert testimony); Alpine Immune Sciences - Consultancy (Includes expert testimony); Diagonal - Consultancy (Includes expert testimony); Terremoto - Consultancy (Includes expert testimony); Pharmacosmos - Consultancy (Includes expert testimony); Atavistik - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony)